KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants.

Phoebe Wen Lin Tay, Cheng Han Ng, Snow Yunni Lin, Yip Han Chin, Jieling Xiao, Wen Hui Lim, Sze Yinn Lim, Clarissa Elysia Fu, Kai En Chan, Jingxuan Quek, Darren Jun Hao Tan, Nicholas Chew, Nicholas Syn, Taisei Keitoku, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Mazen Noureddin, Mark Muthiah, Daniel Q Huang, Rohit Loomba

Am J Gastroenterol 118(4) 645-653

PMID36191268
PMCIDPMC10792533
DOI10.14309/ajg.0000000000002042
发表日期2022-10-03
摘要

摘要

INTRODUCTION: In the absence of an effective treatment for non-alcoholic steatohepatitis (NASH), a randomized, placebo-controlled trial (RCT) remains the current gold standard study design in NASH. As NASH is a largely asymptomatic disease, the side effects of potential therapies require careful evaluation, therefore a pooled rate of the adverse events (AEs) in placebo-treated patients serves as a useful comparator for safety. Therefore, we performed a systematic review and meta-analysis to estimate the rate of AEs among participants in the placebo arm of NASH RCTs. METHODS: Medline, Embase and Cochrane Central Register of Controlled Trials were searched to include clinical trials in phase 2-4 NASH RCTs with placebo treatment arms. A pooled proportions of AEs were analyzed using a generalized linear mixed model with Clopper-Pearson intervals. RESULTS: A total of 41 RCTs (2,944 participants on placebo) were included in this meta-analysis. A total of 68% (confidence interval [CI] 55%-77%) of participants on placebo experienced an AE, 7.8% (5.7%-10%) experienced serious AEs and 3.1% (CI: 1.9%-5.1%) experienced AEs leading to discontinuation. A significantly higher proportion of participants experienced serious AEs in phase 3 studies compared to in phase 2 studies ( P < 0.01) and in pharmaceutical funded studies as compared to studies which were federal-funded studies ( P < 0.01). An analysis of clinical trials evaluating bile acid modulating agents determined that 10% (CI: 5.5%-18%) of participants receiving placebo developed pruritus. DISCUSSION: The present study summarizes the AEs with NASH placebo. Among participants in the placebo arm in NASH, two-third experienced an AE, and nearly 10% experienced a serious AE.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。